Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Risk of malignancy and neoplasia predicted by three molecular testing platforms in indeterminate thyroid nodules on fine-needle aspiration.

Partyka KL, Trevino K, Randolph ML, Cramer H, Wu HH.

Diagn Cytopathol. 2019 Sep;47(9):853-862. doi: 10.1002/dc.24250. Epub 2019 Jun 27.

PMID:
31245935
2.

The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.

Staal B, Liu Y, Barnett D, Hsueh P, He Z, Gao C, Partyka K, Hurd MW, Singhi AD, Drake RR, Huang Y, Maitra A, Brand RE, Haab BB.

Clin Cancer Res. 2019 May 1;25(9):2745-2754. doi: 10.1158/1078-0432.CCR-18-3310. Epub 2019 Jan 7.

PMID:
30617132
3.

Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: A comparison of two proprietary testing platforms.

Partyka KL, Randolph ML, Lawrence KA, Cramer H, Wu HH.

Diagn Cytopathol. 2018 Apr;46(4):320-325. doi: 10.1002/dc.23902. Epub 2018 Feb 15.

PMID:
29446257
4.

The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells.

Barnett D, Liu Y, Partyka K, Huang Y, Tang H, Hostetter G, Brand RE, Singhi AD, Drake RR, Haab BB.

Sci Rep. 2017 Jun 22;7(1):4020. doi: 10.1038/s41598-017-04164-z.

5.

Fine-needle aspirates of thyroid microcarcinoma.

Partyka KL, Wu HH.

J Am Soc Cytopathol. 2017 Nov - Dec;6(6):236-241. doi: 10.1016/j.jasc.2017.06.006. Epub 2017 Jun 29.

PMID:
31043293
6.

A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas.

Sinha J, Cao Z, Dai J, Tang H, Partyka K, Hostetter G, Simeone DM, Feng Z, Allen PJ, Brand RE, Haab BB.

PLoS One. 2016 Dec 19;11(12):e0167070. doi: 10.1371/journal.pone.0167070. eCollection 2016.

7.

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.

Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, Rogers M, Robinson WA, Robinson SE, Applegate AJ, Amato CM, Luo Y, Fujita M, Norris DA, Shellman YG.

Oncotarget. 2016 Dec 20;7(51):84594-84607. doi: 10.18632/oncotarget.13141.

8.

Characterizing Protein Glycosylation through On-Chip Glycan Modification and Probing.

Reatini BS, Ensink E, Liau B, Sinha JY, Powers TW, Partyka K, Bern M, Brand RE, Rudd PM, Kletter D, Drake R, Haab BB.

Anal Chem. 2016 Dec 6;88(23):11584-11592. Epub 2016 Nov 15.

9.

Glycans related to the CA19-9 antigen are elevated in distinct subsets of pancreatic cancers and improve diagnostic accuracy over CA19-9.

Tang H, Partyka K, Hsueh P, Sinha JY, Kletter D, Zeh H, Huang Y, Brand RE, Haab BB.

Cell Mol Gastroenterol Hepatol. 2016 Feb 1;2(2):201-221.e15.

10.

Histologic and clinical follow-up of thyroid fine-needle aspirates in pediatric patients.

Partyka KL, Huang EC, Cramer HM, Chen S, Wu HH.

Cancer Cytopathol. 2016 Jul;124(7):467-71. doi: 10.1002/cncy.21713. Epub 2016 Mar 11.

11.

Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.

Haab BB, Huang Y, Balasenthil S, Partyka K, Tang H, Anderson M, Allen P, Sasson A, Zeh H, Kaul K, Kletter D, Ge S, Bern M, Kwon R, Blasutig I, Srivastava S, Frazier ML, Sen S, Hollingsworth MA, Rinaudo JA, Killary AM, Brand RE.

PLoS One. 2015 Oct 2;10(10):e0139049. doi: 10.1371/journal.pone.0139049. eCollection 2015.

12.

Upregulation of glycans containing 3' fucose in a subset of pancreatic cancers uncovered using fusion-tagged lectins.

Singh S, Pal K, Yadav J, Tang H, Partyka K, Kletter D, Hsueh P, Ensink E, Kc B, Hostetter G, Xu HE, Bern M, Smith DF, Mehta AS, Brand R, Melcher K, Haab BB.

J Proteome Res. 2015 Jun 5;14(6):2594-605. doi: 10.1021/acs.jproteome.5b00142. Epub 2015 May 12.

13.

Glycan motif profiling reveals plasma sialyl-lewis x elevations in pancreatic cancers that are negative for sialyl-lewis A.

Tang H, Singh S, Partyka K, Kletter D, Hsueh P, Yadav J, Ensink E, Bern M, Hostetter G, Hartman D, Huang Y, Brand RE, Haab BB.

Mol Cell Proteomics. 2015 May;14(5):1323-33. doi: 10.1074/mcp.M114.047837. Epub 2015 Mar 2.

14.

First measurement of neutrino and antineutrino coherent charged pion production on argon.

Acciarri R, Adams C, Asaadi J, Baller B, Bolton T, Bromberg C, Cavanna F, Church E, Edmunds D, Ereditato A, Farooq S, Fleming B, Greenlee H, Hatcher R, Horton-Smith G, James C, Klein E, Lang K, Laurens P, Mehdiyev R, Page B, Palamara O, Partyka K, Rameika G, Rebel B, Santos E, Schukraft A, Soderberg M, Spitz J, Szelc AM, Weber M, Yang T, Zeller GP; ArgoNeuT Collaboration.

Phys Rev Lett. 2014 Dec 31;113(26):261801. Epub 2014 Dec 23. Erratum in: Phys Rev Lett. 2015 Jan 23;114(3):039901.

PMID:
25615307
15.

Detection of distinct glycosylation patterns on human γ-glutamyl transpeptidase 1 using antibody-lectin sandwich array (ALSA) technology.

West MB, Partyka K, Feasley CL, Maupin KA, Goppallawa I, West CM, Haab BB, Hanigan MH.

BMC Biotechnol. 2014 Dec 6;14:101. doi: 10.1186/s12896-014-0101-0.

16.

Array-based immunoassays with rolling-circle amplification detection.

Partyka K, Wang S, Zhao P, Cao B, Haab B.

Methods Mol Biol. 2014;1105:3-15. doi: 10.1007/978-1-62703-739-6_1.

PMID:
24623215
17.

Using antibody arrays to measure protein abundance and glycosylation: considerations for optimal performance.

Haab BB, Partyka K, Cao Z.

Curr Protoc Protein Sci. 2013 Sep 24;73:Unit 27.6. doi: 10.1002/0471140864.ps2706s73.

18.

Characterization of glycoproteins in pancreatic cyst fluid using a high-performance multiple lectin affinity chromatography platform.

Gbormittah FO, Haab BB, Partyka K, Garcia-Ott C, Hancapie M, Hancock WS.

J Proteome Res. 2014 Jan 3;13(1):289-99. doi: 10.1021/pr400813u. Epub 2013 Dec 13.

19.

Prediction of glycan motifs using quantitative analysis of multi-lectin binding: Motifs on MUC1 produced by cultured pancreatic cancer cells.

McCarter C, Kletter D, Tang H, Partyka K, Ma Y, Singh S, Yadav J, Bern M, Haab BB.

Proteomics Clin Appl. 2013 Oct;7(9-10):632-41. doi: 10.1002/prca.201300069. Epub 2013 Sep 13.

20.

The Marker State Space (MSS) method for classifying clinical samples.

Fallon BP, Curnutte B, Maupin KA, Partyka K, Choi S, Brand RE, Langmead CJ, Tembe W, Haab BB.

PLoS One. 2013 Jun 4;8(6):e65905. doi: 10.1371/journal.pone.0065905. Print 2013.

21.

Modulation of glycan detection on specific glycoproteins by lectin multimerization.

Cao Z, Partyka K, McDonald M, Brouhard E, Hincapie M, Brand RE, Hancock WS, Haab BB.

Anal Chem. 2013 Feb 5;85(3):1689-98. doi: 10.1021/ac302826a. Epub 2013 Jan 16.

22.

ABT-737 synergizes with Bortezomib to kill melanoma cells.

Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, Gonzalez R, Lewis K, Norris DA, Shellman YG.

Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16.

23.

MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD).

Reuland SN, Smith SM, Bemis LT, Goldstein NB, Almeida AR, Partyka KA, Marquez VE, Zhang Q, Norris DA, Shellman YG.

J Invest Dermatol. 2013 May;133(5):1286-93. doi: 10.1038/jid.2012.400. Epub 2012 Nov 29.

24.

First measurements of inclusive muon neutrino charged current differential cross sections on argon.

Anderson C, Antonello M, Baller B, Bolton T, Bromberg C, Cavanna F, Church E, Edmunds D, Ereditato A, Farooq S, Fleming B, Greenlee H, Guenette R, Haug S, Horton-Smith G, James C, Klein E, Lang K, Laurens P, Linden S, McKee D, Mehdiyev R, Page B, Palamara O, Partyka K, Patch A, Rameika G, Rebel B, Rossi B, Soderberg M, Spitz J, Szelc AM, Weber M, Yang T, Zeller G; ArgoNeuT Collaboration.

Phys Rev Lett. 2012 Apr 20;108(16):161802. Epub 2012 Apr 20.

PMID:
22680709
25.

Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation.

Partyka K, Maupin KA, Brand RE, Haab BB.

Proteomics. 2012 Jul;12(13):2212-20. doi: 10.1002/pmic.201100676.

26.

Comparison of surgical and endoscopic sample collection for pancreatic cyst fluid biomarker identification.

Partyka K, McDonald M, Maupin KA, Brand R, Kwon R, Simeone DM, Allen P, Haab BB.

J Proteome Res. 2012 May 4;11(5):2904-11. doi: 10.1021/pr2012736. Epub 2012 Apr 4.

27.

Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers.

Yue T, Maupin KA, Fallon B, Li L, Partyka K, Anderson MA, Brenner DE, Kaul K, Zeh H, Moser AJ, Simeone DM, Feng Z, Brand RE, Haab BB.

PLoS One. 2011;6(12):e29180. doi: 10.1371/journal.pone.0029180. Epub 2011 Dec 29.

28.

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.

Reuland SN, Goldstein NB, Partyka KA, Cooper DA, Fujita M, Norris DA, Shellman YG.

PLoS One. 2011;6(8):e24294. doi: 10.1371/journal.pone.0024294. Epub 2011 Aug 29.

29.

Identification of blood-protein carriers of the CA 19-9 antigen and characterization of prevalence in pancreatic diseases.

Yue T, Partyka K, Maupin KA, Hurley M, Andrews P, Kaul K, Moser AJ, Zeh H, Brand RE, Haab BB.

Proteomics. 2011 Sep;11(18):3665-74. doi: 10.1002/pmic.201000827. Epub 2011 Aug 2.

30.

[Successful treatment with bacteriophage in purulent cerebrospinal meningitis in a newborn].

Strój L, Weber-Dabrowska B, Partyka K, Mulczyk M, Wójcik M.

Neurol Neurochir Pol. 1999 May-Jun;33(3):693-8. Polish.

PMID:
10540729

Supplemental Content

Loading ...
Support Center